Startup StimGuard has positive early data for injectable incontinence micro-stimulator as it heads into U.S. pivotal trial

StimGuard's injectable tibial stimulator--Courtesy of StimGuard

StimGuard reported pilot data for its novel wireless microtechnology injectable tibial stimulator for the relief of overactive bladder. The move comes just as the startup plans to launch a U.S. pivotal trial for the device this summer. It expects to get the incontinence device through clinical testing to enable a CE mark this year and to submit it for approval to the FDA in 2016.

Urinary incontinence can already be treated with neurostimulation, but the procedure currently requires routine office visits or surgery, according to the company. StimGuard is hoping that its device will simply be injected in the urologist's office, perhaps making its use easy and common. More than 200 million people globally have urinary incontinence--a figure that is only slated to climb as the elderly population grows.

The company itself remains a bit shrouded in mystery, having just come out with its first statement announcing the upcoming U.S. pivotal trial earlier this month. FierceMedicalDevices reached out for further information about the history of the company and its investors, but hadn't received a response by press time.

In December, Medtronic ($MDT) acquired another urinary incontinence startup, Advanced Uro-Solutions, for an undisclosed sum. It expects to launch its product, the 510(k)-cleared tibial stimulator Nuro, this year; it requires ongoing 30-minute treatments three to four times weekly via a 34-gauge needle that's placed near the ankle. Medtronic already markets a sacral neurostimulator that is implanted surgically to treat incontinence called InterStim.

The data for the StimGuard Tibial System seem promising but quite preliminary. StimGuard reduced voiding episodes by more than 80% on average in only two patients with incontinence. The prospective, randomized, controlled U.S. trial aims to include 60 patients from 5 centers.

"The therapy is utilized for just eight hours a day, so it can be conveniently administered using only a sock worn during the evening or overnight," said StimGuard Director James McGivern in a statement. "Chronic tibial stimulation affects multiple afferent paths to the micturition centers, possibly better serving patients than classic sacral neurostimulation over the long term."

The primary efficacy endpoint for the pivotal trial will be the reduction in number of urgent incontinence episodes as reported in a three-day diary. The trial will include women and men with at least four incontinence episodes that are associated with urge as recorded in a three-day diary with at least one episode per 24 hours.

Patients will be randomized to one of two arms: an SNS treatment group and a control arm in which the SNS device will be implanted but not activated until 90 days after implantation.

The technology includes a quadripolar stimulator with an embedded receiver; the implanted device is only 1.3 mm in diameter. The patient wears a small, external, rechargeable transmitter that powers the implant and sends the selected therapy program.

"I am extremely excited about this new technology developed by StimGuard," said Dr. Chris Winters, chairman of the Department of Urology at Louisiana State University, in a statement. "Now people with overactive bladder will have additional options, including the ability to receive a permanent implant with a far less invasive and complicated surgery in an office setting. The StimGuard Tibial System is well positioned to revolutionize the urology industry with an interventional method that most urologists will be able to easily integrate into their practices."

- here is the release

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

To bring its nerve-stimulating wearable to market, Cala Health collected $50 million that it also plans to use to expand its therapeutic pipeline.

The FDA cleared a handful of diagnostics aimed at STIs, including the first to detect chlamydia and gonorrhea outside the genitals.